FierceHealthIT

AUGUST 29, 2023

The Biden administration and federal regulators may be taking a victory lap following the unveiling of the Centers for Medicare & Medicaid Services’ (CMS') price negotiations list, but major pl | Critics of President Joe Biden's policies to rein in prices for 10 Medicare Part D drugs believe the policy is "draconian" and will (..)

Pharmaceuticals 96

Pharmaceuticals BioTech Medicare 96

Health Populi

MAY 8, 2019

In 2018, we saw more incentives to inspire adherence to prescription drug regimens, particularly in Medicare Part D along with increasing focus by pharmacists and providers. For people enrolled in Medicare Part D, 20% faced over $500 in OOP costs. Patients abandon over 20% of new prescriptions when their OOP costs rise above $50.

Medicare 149

Medicare BioTech Pharmaceuticals Mental health 149

Health Populi

MAY 14, 2018

Smart Pharmaceuticals Index (NQSSPH) from May 11, 2018, the date when POTUS and Secretary Azar made their announcement. Incentives for lowering list prices for medicines, such as FDA requiring that drug companies include list prices in ads and bringing more transparency to Medicare drug pricing and generic competition, and.

Pharmaceuticals 120

Pharmaceuticals Medicare Life Science BioTech 120

Healthcare IT Today

JANUARY 9, 2023

This is not sustainable when so many of the active pharmaceutical ingredients and medical device components we rely on come from a small handful of countries. This could be a breakthrough for the pharmaceutical industry. Lauren Ohlsson, Lead of Industry Solutions – Pharmaceuticals & Healthcare at VDX.tv.

Health IT 94

Health IT Pharmaceuticals Drug Development Life Science 94

Health Populi

MARCH 13, 2018

Specifically, $19 billion worth of biotech spending will find biosimilar competition starting in 2018 for the first time. The report pointed especially to hospital and pharmaceutical prices. As we know from the Trump Administration in power for the past fourteen months, we must keep our collective eye on this ball on a daily basis.

Telehealth 168

Telehealth Pharmaceuticals BioTech Medicare 168

Health Populi

JUNE 18, 2020

The authors, Dr. Naci and Dr. Kesselheim, are affiliated with the London School of Economics and Brigham and Women’s Hospital in Boston, note that 1% of medicines dispensed under Medicare Part D and Medicaid accounted for nearly $1 in $3 of drug spending in each program in 2015. bn to $32.8 bn to $9.9 bn for Medicaid.

BioTech 191

BioTech Medicare Life Science Telehealth 191

Health Populi

MARCH 6, 2019

is prescription drug prices — that they’re too high, that the Federal government should negotiate to lower costs for Medicare enrollees, and that out-of-pocket costs for drugs should be limited. That would be profits made by pharmaceutical companies, cited by 80% of respondents. consumers were asked.

Pharmaceuticals 140

Pharmaceuticals Life Science Medicare BioTech 140

Health Populi

AUGUST 16, 2021

There is one health care public policy issue that unites U.S. voters across political party: that is the consumer-facing costs of prescription drugs.

Pharmaceuticals 323

Pharmaceuticals Telehealth BioTech Mental health 323

Insulin Nation

DECEMBER 8, 2016

Drug pricing was not the centerpiece of his populist rhetoric, but on the campaign trail he did briefly describe his plans to have Medicare negotiate for better drug prices; he also signaled his intent to remove hurdles to importing cheaper drugs made abroad. This might be what he’s doing with drug companies, as well.

BioTech 56

BioTech Pharmaceuticals Medicare 56

Health Populi

JUNE 3, 2021

adults note that expanding Medicare to including hearing aids, dental and vision coverage would be their top or an important priority, shown in the second line in the bar chart on public priorities. States to negotiate with drug companies to get lower prices on Rx meds in their state, and. On the cost-front, 90% of U.S.

Medicare 170

Medicare Life Science BioTech Pharmaceuticals 170

Health Populi

MAY 19, 2019

They don’t tend to shop around for health care or be super-engaged in their care, probably because they tend to be older and more likely to be covered by Medicare. They may be threatened by a call for “Medicare for All” given their affection for the program.

Life Science 149

Life Science BioTech Medicare Medical Billing 149